Helomics knows that chemotherapy isn't "one size fits all." That's why the company developed and markets ChemoFx, a product that examines the response of a specific patient's tumor to various chemotherapies. Physicians can use the test to collect cells from a solid tumor, then Helomics performs tissue cultures and tries various chemotherapeutic and biologic agents to measure the best type, combination, and dose of chemotherapy to help combat the disease in individual patients. The company has been studying ChemoFx use with ovarian and breast tumors, among others. The company markets its products and services through a direct sales force. Helomics is a subsidiary of Precision Therapeutics.
See detailed business credit reports on other businesses or your own.
See detailed profiles for insights and prospects on this company's top competitors.
Get in Touch with 4 Contacts and 1 Principals*
Gerald J Vardzel JuniorChief Executive Officer and President
Amy EwingClinical Laboratory Supervisor
Arlette UihleinVice President Pathology Services And Medical Director
Mark CollinsChief Technology Officer